These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9447474)

  • 1. A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects.
    Soto J; Alsar MJ
    J Clin Pharm Ther; 1997 Jun; 22(3):191-5. PubMed ID: 9447474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on theophylline metabolism: autoinduction and inhibition by antipyrine.
    Denlinger CL; Stryker KK; Slusher LB; Vesell ES
    Clin Pharmacol Ther; 1987 May; 41(5):522-30. PubMed ID: 3568537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity.
    Matzke GR; Frye RF; Early JJ; Straka RJ; Carson SW
    Pharmacotherapy; 2000 Feb; 20(2):182-90. PubMed ID: 10678296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeine pharmacokinetics in obesity and following significant weight reduction.
    Caraco Y; Zylber-Katz E; Berry EM; Levy M
    Int J Obes Relat Metab Disord; 1995 Apr; 19(4):234-9. PubMed ID: 7627246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of age and sex on metabolism and urinary excretion of antipyrine.
    Jorquera F; Almar M; Pozuelo M; Sansegundo D; González-Sastre M; González-Gallego J
    J Gerontol A Biol Sci Med Sci; 1998 Jan; 53(1):M14-9. PubMed ID: 9467428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of antipyrine kinetics from saliva or plasma: influence of age.
    Jorquera F; Almar MM; Jimeno A; González-Sastre M; González-Gallego J
    J Pharm Biomed Anal; 1995 Aug; 13(9):1141-5. PubMed ID: 8573640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between antipyrine and aminopyrine.
    Vesell ES; Passananti GT; Hepner GW
    Clin Pharmacol Ther; 1976 Dec; 20(6):661-9. PubMed ID: 991537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the time course of drugs with inhibitory effects on hepatic metabolic activity using successive salivary caffeine tests.
    Soto J; Alsar MJ; Sacristan JA
    Pharmacotherapy; 1995; 15(6):781-4. PubMed ID: 8602388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
    Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
    Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
    Shaw PN; Houston JB; Rowland M; Hopkins K; Thiercelin JF; Morselli PL
    Br J Clin Pharmacol; 1985 Dec; 20(6):611-8. PubMed ID: 4091993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.
    Rivière JH; Back DJ; Breckenridge AM; Howells RE
    Br J Clin Pharmacol; 1985 Nov; 20(5):469-74. PubMed ID: 3878153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipyrine and caffeine dispositions in clinically normal dogs and dogs with progressive liver disease.
    Boothe DM; Cullen JM; Calvin JA; Jenkins WL; Brown SA; Green RA; Corrier DE
    Am J Vet Res; 1994 Feb; 55(2):254-61. PubMed ID: 8172417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of smoking on caffeine elimination: implications for its use as a semiquantitative test of liver function.
    Murphy TL; McIvor C; Yap A; Cooksley WG; Halliday JW; Powell LW
    Clin Exp Pharmacol Physiol; 1988 Jan; 15(1):9-13. PubMed ID: 2482799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analgesic effects of propyphenazone in comparison to its combination with caffeine.
    Kraetsch HG; Hummel T; Lötsch J; Kussat R; Kobal G
    Eur J Clin Pharmacol; 1996; 49(5):377-82. PubMed ID: 8866632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of antipyrine from saliva as a measure of metabolism in man.
    Welch RM; DeAngelis RL; Wingfield M; Farmer TW
    Clin Pharmacol Ther; 1975 Sep; 18(3):249-58. PubMed ID: 1164815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of the one-sample method for determination of antipyrine clearance in elderly subjects.
    Jorquera F; Almar MM; González-Sastre M; Suarez I; González-Gallego J
    J Pharm Biomed Anal; 1996 Oct; 15(1):7-11. PubMed ID: 8895071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.
    Danhof M; van Zuilen A; Boeijinga JK; Breimer DD
    Eur J Clin Pharmacol; 1982; 21(5):433-41. PubMed ID: 7075648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.
    Greenblatt DJ; Allen MD; MacLaughlin DS; Huffman DH; Harmatz JS; Shader RI
    J Pharmacokinet Biopharm; 1979 Apr; 7(2):159-79. PubMed ID: 20218012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of salivary caffeine tests to assess the inducer effect of a drug on hepatic metabolism.
    Soto J; Sacristan JA; Alsar MJ
    Ann Pharmacother; 1996; 30(7-8):736-9. PubMed ID: 8826551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.